Mechanistic Insights From Longitudinal Changes in Blood and Urine Proteins to Explain Efficacy and Safety of Torsemide vs Furosemide After a Heart Failure Hospitalization
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 9
- 主要终点
- Differences in proteomic protein clusters between treatment groups
研究概览
简要总结
Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.
详细描述
Patients who are enrolling in the TRANSFORM-HF study or being prescribed Torsemide or Furosemide at hospital discharge will provide blood and urine at the time of study enrollment (within 72 hours of hospital discharge) and at 90 days (+/- one week) after hospital discharge.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participation in the TRANSFORM-HF trial or prescription of Torsemide or Furosemide
- •Willing to provide blood and urine sample at enrollment and follow-up
排除标准
- •Inability or unwillingness to comply with the study requirements
结局指标
主要结局
Differences in proteomic protein clusters between treatment groups
时间窗: baseline
How the biomarkers are different between groups
Differences in trajectories of protein clusters between treatment groups
时间窗: 90 days
How the protein clusters change over time from baseline to 90 days
次要结局
- Differences in single biomarkers and biomarker trajectories between treatment groups(baseline and 90 days)
- Differences in urinary protein levels between treatment groups(baseline)